Kailera Therapeutics Reports Positive Phase 3 Results for HRS-7535
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials conducted by its partner, Hengrui Pharma, evaluating the oral small molecule candidate HRS-7535, also known as KAI-7535. In the HARBOR-1 trial for obesity, the candidate achieved a mean weight loss of up to 10.9% at week 44 and 11.1% at week 50. In the OUTSTAND-2 trial for type 2 diabetes, the once-daily drug met its primary endpoint of non-inferiority to dapagliflozin, reducing blood sugar levels by up to 1.68% at week 32. Kailera is concurrently evaluating KAI-7535 in an ongoing global Phase 2 trial for obesity, with results expected in 2027. "The HRS-7535 Phase 3 results highlight the promise of oral small molecules as a treatment option for people living with obesity, with the potential to combine clinically meaningful weight loss with convenience, scalability, and accessibility," said Scott Wasserman, chief medical officer, Kailera.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KLRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KLRA
Wall Street analysts forecast KLRA stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.300
Low
Averages
High
Current: 23.300
Low
Averages
High
About KLRA
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on obesity care. The Company is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The Company is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kailera Therapeutics Shares Drop Over 10% After Trial Data
- Clinical Trial Results: Kailera Therapeutics reported topline data from two late-stage trials in China, where although the HARBOR-1 and OUTSTAND-2 trials met their primary endpoints, the weight loss results of 8.0% and 9.8% in HARBOR-1 fall significantly short of existing GLP-1 drugs, indicating a lack of competitive edge in the market.
- Adverse Effects Impact: The HARBOR-1 trial revealed that mild-to-moderate gastrointestinal side effects were prevalent, with approximately 4% and 3% of patients dropping out due to treatment-emergent adverse events for the 120 mg and 180 mg doses of HRS-7535, respectively, suggesting potential issues with drug tolerability that could affect patient adherence.
- Global Trial Progress: Kailera's ongoing Phase 2 global clinical trial commenced in April, aiming to optimize KAI-7535 for a diverse group of obese patients, with data expected in 2027, a timeline that could influence investor perceptions of the company's future potential.
- Market Competition Pressure: Compared to existing oral GLP-1 drugs from Novo Nordisk and Lilly, Kailera's HRS-7535 shows significantly lower weight loss efficacy, which may lead to a loss of market share in the rapidly growing weight-loss drug sector, impacting the company's long-term market positioning.
See More
Kalohexis Files for Potential U.S. IPO
- IPO Filing Progress: Kalohexis confidentially filed for a potential initial public offering with the SEC on Tuesday, marking its debut as a biotech firm, although it has yet to finalize the number of shares and pricing range.
- Market Positioning: As a spinout of Endevica Bio, Kalohexis focuses on developing a range of peptide therapies targeting the melanocortin system, addressing the growing treatment needs for obesity and cachexia associated with cancer.
- Lead Asset Development: Its lead asset, mifomelatide, is in mid-stage development for treating cachexia related to advanced cancers, while another candidate, 710GO, is in early-stage development aimed at obesity patients.
- Industry Trend: If successful, Kalohexis will become the latest obesity drug developer to go public in the U.S., following Kailera Therapeutics' $625 million offering in April, further fueling the IPO momentum in the biotech sector.
See More
Kailera's HRS-7535 Clinical Trials Show Positive Results
- Significant Weight Loss: In the HARBOR-1 Phase 3 trial conducted in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44, demonstrating its efficacy in obesity treatment, which could provide a competitive edge for the company in the market.
- Diabetes Improvement: In the OUTSTAND-2 Phase 3 trial, HRS-7535 lowered HbA1c by an average of 1.68% at Week 32, indicating its potential application in type 2 diabetes patients, thereby broadening Kailera's product portfolio.
- Good Safety Profile: Both Phase 3 trials showed no liver safety signals, with most treatment-emergent adverse events being mild to moderate, enhancing the appeal of HRS-7535 as a safe treatment option, which may improve patient adherence.
- Global Trial Expansion: Kailera is conducting a global Phase 2 trial of KAI-7535, with data expected in 2027, showcasing the company's ongoing innovation and market expansion potential in obesity treatment.
See More
Pfizer Eyes Kailera Acquisition to Expand Weight Loss Portfolio
- Vaccine Dependency Decline: Pfizer has significantly underperformed over the past three years, primarily due to its reliance on COVID-19 vaccines, which have seen declining vaccination rates, putting pressure on sales and impacting overall market performance.
- Acquisition Potential: CEO Albert Bourla highlighted the company's 'very big balance sheet,' indicating its capability to pursue potential acquisitions in the future, despite having made several buyouts in recent years, reflecting a proactive approach to business expansion.
- Weight Loss Market Opportunity: Pfizer bolstered its weight loss portfolio by acquiring Metsera for up to $10 billion, with its lead asset MET-097i now in phase 3 trials, showcasing the company's strategic positioning in the rapidly growing anti-obesity market.
- Attractiveness of Kailera: Kailera Therapeutics' leading candidate ribupatide mimics the actions of two gut hormones, potentially offering a competitive edge in the weight loss market; acquiring Kailera would significantly enhance Pfizer's differentiated pipeline in this sector.
See More
Kardigan's Shares Rise 1.6% in Successful Nasdaq Debut
- Strong Market Debut: Kardigan raised $400 million in its Nasdaq IPO, with shares opening at $16.25, reflecting a 1.6% increase from the IPO price of $16, indicating robust investor interest in biotech firms.
- Oversubscription Details: The company sold 25 million shares at $16 each on Wednesday, exceeding its marketed range of $14 to $16, showcasing investor confidence in its heart drug development.
- Improving Market Conditions: The successful debut highlights a recovering market environment for biotech, as investor appetite for companies with advanced clinical programs and promising drug pipelines is on the rise.
- Industry Trend: Kardigan's listing adds to a series of successful biotech IPOs this year, reinforcing the sector's investment appeal, particularly as it develops precision medicines for cardiovascular diseases.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
Kailera Therapeutics Shares Drop Over 10% After Trial Data
- Clinical Trial Results: Kailera Therapeutics reported topline data from two late-stage trials in China, where although the HARBOR-1 and OUTSTAND-2 trials met their primary endpoints, the weight loss results of 8.0% and 9.8% in HARBOR-1 fall significantly short of existing GLP-1 drugs, indicating a lack of competitive edge in the market.
- Adverse Effects Impact: The HARBOR-1 trial revealed that mild-to-moderate gastrointestinal side effects were prevalent, with approximately 4% and 3% of patients dropping out due to treatment-emergent adverse events for the 120 mg and 180 mg doses of HRS-7535, respectively, suggesting potential issues with drug tolerability that could affect patient adherence.
- Global Trial Progress: Kailera's ongoing Phase 2 global clinical trial commenced in April, aiming to optimize KAI-7535 for a diverse group of obese patients, with data expected in 2027, a timeline that could influence investor perceptions of the company's future potential.
- Market Competition Pressure: Compared to existing oral GLP-1 drugs from Novo Nordisk and Lilly, Kailera's HRS-7535 shows significantly lower weight loss efficacy, which may lead to a loss of market share in the rapidly growing weight-loss drug sector, impacting the company's long-term market positioning.
See More
Kalohexis Files for Potential U.S. IPO
- IPO Filing Progress: Kalohexis confidentially filed for a potential initial public offering with the SEC on Tuesday, marking its debut as a biotech firm, although it has yet to finalize the number of shares and pricing range.
- Market Positioning: As a spinout of Endevica Bio, Kalohexis focuses on developing a range of peptide therapies targeting the melanocortin system, addressing the growing treatment needs for obesity and cachexia associated with cancer.
- Lead Asset Development: Its lead asset, mifomelatide, is in mid-stage development for treating cachexia related to advanced cancers, while another candidate, 710GO, is in early-stage development aimed at obesity patients.
- Industry Trend: If successful, Kalohexis will become the latest obesity drug developer to go public in the U.S., following Kailera Therapeutics' $625 million offering in April, further fueling the IPO momentum in the biotech sector.
See More
Kailera's HRS-7535 Clinical Trials Show Positive Results
- Significant Weight Loss: In the HARBOR-1 Phase 3 trial conducted in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44, demonstrating its efficacy in obesity treatment, which could provide a competitive edge for the company in the market.
- Diabetes Improvement: In the OUTSTAND-2 Phase 3 trial, HRS-7535 lowered HbA1c by an average of 1.68% at Week 32, indicating its potential application in type 2 diabetes patients, thereby broadening Kailera's product portfolio.
- Good Safety Profile: Both Phase 3 trials showed no liver safety signals, with most treatment-emergent adverse events being mild to moderate, enhancing the appeal of HRS-7535 as a safe treatment option, which may improve patient adherence.
- Global Trial Expansion: Kailera is conducting a global Phase 2 trial of KAI-7535, with data expected in 2027, showcasing the company's ongoing innovation and market expansion potential in obesity treatment.
See More
Pfizer Eyes Kailera Acquisition to Expand Weight Loss Portfolio
- Vaccine Dependency Decline: Pfizer has significantly underperformed over the past three years, primarily due to its reliance on COVID-19 vaccines, which have seen declining vaccination rates, putting pressure on sales and impacting overall market performance.
- Acquisition Potential: CEO Albert Bourla highlighted the company's 'very big balance sheet,' indicating its capability to pursue potential acquisitions in the future, despite having made several buyouts in recent years, reflecting a proactive approach to business expansion.
- Weight Loss Market Opportunity: Pfizer bolstered its weight loss portfolio by acquiring Metsera for up to $10 billion, with its lead asset MET-097i now in phase 3 trials, showcasing the company's strategic positioning in the rapidly growing anti-obesity market.
- Attractiveness of Kailera: Kailera Therapeutics' leading candidate ribupatide mimics the actions of two gut hormones, potentially offering a competitive edge in the weight loss market; acquiring Kailera would significantly enhance Pfizer's differentiated pipeline in this sector.
See More
Kardigan's Shares Rise 1.6% in Successful Nasdaq Debut
- Strong Market Debut: Kardigan raised $400 million in its Nasdaq IPO, with shares opening at $16.25, reflecting a 1.6% increase from the IPO price of $16, indicating robust investor interest in biotech firms.
- Oversubscription Details: The company sold 25 million shares at $16 each on Wednesday, exceeding its marketed range of $14 to $16, showcasing investor confidence in its heart drug development.
- Improving Market Conditions: The successful debut highlights a recovering market environment for biotech, as investor appetite for companies with advanced clinical programs and promising drug pipelines is on the rise.
- Industry Trend: Kardigan's listing adds to a series of successful biotech IPOs this year, reinforcing the sector's investment appeal, particularly as it develops precision medicines for cardiovascular diseases.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
